<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) continues to rank as the third most common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in Western society and the second leading cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> in North America </plain></SENT>
<SENT sid="1" pm="."><plain>There are at least three distinct, and relatively discreet, molecular pathways associated with this disease: <z:mp ids='MP_0008866'>chromosomal instability</z:mp> (CIN), microsatellite instability (MSI) and the <z:chebi fb="1" ids="16040">cytosine</z:chebi> polyguanine island methylator phenotype </plain></SENT>
<SENT sid="2" pm="."><plain>Defects in the DNA mismatch repair system (MMR) account for the MSI phenotype and genotype of about 15Â % of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Although high frequency MSI <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> have better stage independent prognosis compared to those with CIN, MMR deficient <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> appears to be resistant to fluorouracil based treatment, but sensitive to other therapeutic regimens </plain></SENT>
<SENT sid="4" pm="."><plain>This review summarises current literature on differential chemosensitivity of MMR-deficient <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>